Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27
MG was supported by a post-doctoral fellowship at Boston University. ASK's work was funded by Arnold Ventures and International Collaborative Bioscience Innovation & Law Programme (Novo Nordisk Foundation grant number NNF23SA0087056). While KO is Executive Director of CARB-X, this work was not funded under any CARB-X grant.
Authors
- Maple Goh (ORCID: https://orcid.org/0000-0002-0491-5385)
- M. Gary Newton
- Kevin Outterson (ORCID: https://orcid.org/0000-0003-2513-3216)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Rachel Freeman (ORCID: https://orcid.org/0000-0002-5262-3395)
- Matt McEnany
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- IQVIA (United Kingdom) (GB)
- University of Montana (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-09-08
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103485
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Arnold Ventures
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
- Novo Nordisk
- Novo Nordisk Fonden